Can You Take HRT and a GLP-1 at the Same Time?

Yes, for most women the two can be used together. Menopausal hormone therapy (HRT) replaces the estrogen (and often progesterone) that your ovaries make less of after menopause. A GLP-1 receptor agonist, such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), mimics a gut hormone that lowers appetite and slows digestion. They work through different pathways, and neither drug label lists the other as a contraindication.

That said, "no known conflict" is not the same as "no need to talk to a clinician." Your personal history matters: blood clots, migraine with aura, liver disease, a uterus that still needs progesterone protection, or a history of pancreatitis all change the conversation. A menopause-informed prescriber can look at the whole picture.

Many women end up on both because the timing overlaps. Perimenopause and menopause often bring weight gain around the middle, and that is exactly when many women ask about GLP-1s. If you are still working out where you are in that transition, our [34 symptoms of perimenopause checklist](/blog/the-34-symptoms-of-perimenopause-a-complete-checklist) can help you sort it out first.

The best evidence so far is observational. A retrospective study from Weill Cornell Medicine looked at postmenopausal women taking anti-obesity medications and reported that those who also used menopausal hormone therapy lost more weight than those who did not. Retrospective means researchers looked back at existing records, so they cannot rule out that women who choose HRT differ in other ways, such as engagement with care.

There is also a plausible biology story. Estrogen influences appetite, fat distribution and insulin sensitivity. When estrogen falls, fat tends to shift toward the belly (visceral fat). Restoring estrogen may make the body more responsive to weight-loss efforts, though this has not been proven in a randomized trial.

On the safety side, the WHI 30-year follow-up (Manson et al., JAMA 2024) reported that neither estrogen-plus-progestin nor estrogen-alone therapy increased all-cause mortality over the long term. Timing still matters, which we cover in [the HRT window of opportunity](/blog/the-hrt-window-of-opportunity-why-timing-matters).

Possibly for pills, much less for patches and gels. GLP-1 medications slow gastric emptying, meaning food and pills stay in the stomach longer. For most oral drugs this delay is small and clinically minor. But tirzepatide's prescribing information does advise extra caution with oral hormonal contraceptives, especially after starting and after each dose increase, because absorption can change. It is reasonable to ask whether similar caution applies to oral estrogen.

Transdermal estrogen, meaning a patch, gel or spray, is absorbed through skin and skips the gut and the liver's first pass. That makes levels more predictable when digestion is unpredictable. Transdermal estrogen is also associated with a lower blood clot risk than oral estrogen in observational data; see [HRT and blood clot risk](/blog/hrt-and-blood-clot-risk-does-delivery-method-matter) for the details.

Nausea and vomiting matter too. If you throw up soon after an oral dose, you may not absorb it. Patches sidestep that problem. Progesterone is usually taken as a capsule at night, which many women tolerate well even during dose escalation.

Yes, it can be. Estrogen helps protect bone, and bone loss speeds up around the final menstrual period. Rapid weight loss also tends to reduce bone density and lean mass. In the SURMOUNT-1 trial (NEJM, 2022), about a quarter of weight lost on tirzepatide was lean mass on DXA scans, and lean mass includes muscle. Put those together and you have a "double hit" on the skeleton and muscles.

HRT is one of the most effective treatments for preventing menopausal bone loss, which is a reason some clinicians see HRT as a helpful partner during weight loss. It is not a replacement for the basics, though. Aim for enough protein, resistance exercise two to three times a week, and adequate calcium and vitamin D; our guide to [calcium and vitamin D in menopause](/blog/calcium-vitamin-d-menopause-how-much-you-need) covers targets.

For the muscle side of the story, read [muscle loss on GLP-1s in menopause](/blog/muscle-loss-glp1-menopause-double-risk). If you have never had a bone density (DXA) scan, ask whether it is time for a baseline before or soon after you start.

Start with your own baseline. GLP-1 side effects such as nausea, constipation, fatigue and headaches can look like menopause symptoms, and the reverse is true too. Brain fog, poor sleep, low mood and joint aches show up in both worlds.

A few practical flags: breast tenderness and bloating are common in the first weeks of estrogen. Nausea is common for GLP-1 users after each dose increase. If both begin together, it is hard to know which drug is responsible. That is why many clinicians suggest changing one thing at a time, ideally waiting two to four weeks between changes when possible.

Call your prescriber promptly for severe abdominal pain (especially with vomiting, which can signal pancreatitis or gallbladder problems), unusual vaginal bleeding on HRT, a swollen painful calf, chest pain or sudden shortness of breath. A simple log makes these conversations easier; see [what to track on a GLP-1 during menopause](/blog/glp1-menopause-symptom-tracker-what-to-log-and-why).

There is no single right order, and the choice depends on your symptoms and goals. If hot flashes, night sweats and poor sleep are your biggest problems, starting HRT first can improve your quality of life and may make it easier to exercise and eat well. If metabolic health is the urgent issue, such as type 2 diabetes or a high cardiovascular risk, starting the GLP-1 may be the priority.

Starting together is possible, but it makes side effects harder to interpret. Many clinicians choose the more urgent treatment first and add the second after things settle. HRT often uses a low starting dose and is adjusted after about three months, while GLP-1 doses climb every four weeks or so.

Timing of HRT also matters for safety. Benefits are clearest when it is started before age 60 or within 10 years of menopause, and the risks are less favorable when started much later. The type of estrogen also matters, and we compare options in [bioidentical vs synthetic HRT](/blog/bioidentical-vs-synthetic-hrt-what-the-research-shows).

Some situations call for more care. HRT is generally avoided or used very carefully with a history of breast cancer, estrogen-sensitive cancers, unexplained vaginal bleeding, active liver disease, or a prior blood clot or stroke. GLP-1s carry warnings for a personal or family history of medullary thyroid cancer or MEN2, and for pancreatitis; see [the data on GLP-1s and thyroid cancer risk](/blog/glp1-thyroid-cancer-risk-what-the-data-shows).

If you take oral contraceptives, note that tirzepatide labeling recommends switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. Also, GLP-1s are not recommended in pregnancy, so tell your clinician if you could become pregnant during perimenopause. Periods can be irregular, but ovulation still happens.

Finally, tell every prescriber about all supplements you use. Some herbal products marketed for menopause can interact with medicines or affect the liver.

The hardest part is often not the medication itself but keeping track of what is changing and why. Lea is built for women in exactly this overlap: it can help you build a symptom and side-effect log, prepare questions for your prescriber, and spot patterns such as nausea that flares on injection day or hot flashes that ease after a patch change.

Bring your list to appointments, including doses, start dates and what you noticed. This is not medical advice, and decisions about starting, stopping or changing hormones or GLP-1s belong with a licensed clinician who knows your history.